Effects of olmesartan, an angiotensin II receptor blocker, on peripheral insulin sensitivity in Japanese subjects with type 2 diabetes and hypertension

Internal Medicine

Volumn 51, Issue 16, 2012, Pages 2091-2096

  Shimoda, Seiya ^a   Goto, Rieko ^a   Furukawa, Noboru ^a   Tsuruzoe, Kaku ^a   Kawashima, Junji ^a   Iwashita, Shinsuke ^a   Maeda, Takako ^a   Ichimori, Shinji ^b   Ichinose, Kenshi ^a   Nishida, Kenro ^c   Araki, Eiichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Ueki Hospital   (Japan)

^c Minamata City Hospital and Medical Center   (Japan)

Author keywords

Euglycemic hyperinsulinemic clamp; Insulin sensitivity index; M I value

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; ENZYME IMMUNOASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; JAPANESE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE RATE; SYSTOLIC BLOOD PRESSURE;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERTENSION; IMIDAZOLES; INSULIN RESISTANCE; JAPAN; MALE; MIDDLE AGED; RECEPTOR CROSS-TALK; TETRAZOLES;

EID: 84865115498     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7408     Document Type: Article

References (33)

1. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353: 611-616, 1999.
2. McMurray JJ, Holman RR, Haffner SM, et al; Navigator Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362: 1477-1490, 2010.
3. Uehara M, Kishikawa H, Isami S, et al. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia 37: 300-307, 1994.
4. Isami S, Kishikawa H, Araki E, et al. Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway. Diabetologia 39: 412-420, 1996.
5. Motoshima H, Araki E, Nishiyama T, et al. Bradykinin enhances insulin receptor tyrosine kinase in 32D cells reconstituted with bradykinin and insulin signaling pathways. Diabetes Res Clin Pract 48: 155-170, 2000.
6. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363: 2022-2031, 2004.
7. Moan A, Hoieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE. The Effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 14: 1093-1097, 1996.
8. Laakso M, Karjalainen L, Lempiainen-Kuosa P. Effect of losartan on insulin sensitivity in hypertensive subjects. Hypertension 28: 392-396, 1996.
9. Paolisso G, Tagliamonte MR, Gambardella A, et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulinresistant hypertensive patients. J Hum Hypertens 11: 307-312, 1997.
10. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Parmacol 46: 467-471, 1998.
11. Akel A, Wiecek A, Nowicki M, Kokot F. The effect of treatment with enalapril versus losartan on levels of insulin resistance in patients with essential hypertension. Pol Arch Med Wewn 103: 123-131, 2000.
12. Olsen MH, Fossum E, Hoieggen A, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 23: 891-898, 2005.
13. Krusinova E, Klementova M, Kopecky J, et al. Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subject. Eur J Endocrinol 157: 443-449, 2007.
14. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42: 76-81, 2003.
15. Eriksson JW, Jansson PA, Carlberg B, et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 52: 1030-1037, 2008.
16. Derosa G, Maffioli P, AT Salvadeo S, et al. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res 33: 790-795, 2010.
17. Fogari R, Zoppi A, Salvadeo S, et al. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. Hypertens Res 34: 509-515, 2011.
18. Fogari R, Zoppi A, Ferrari I, et al. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res 41: 893-898, 2009.
19. van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, Diamant M. Valsartan improves β-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care 34: 845-851, 2011.
20. Nishida K, Shimoda S, Ichinose K, Araki E, Shichiri M. What is artificial endocrine pancreas? Mechanism and history. World J Gastroenterol 15: 4105-4110, 2009.
21. DeFronzo RA, Tobin JD, Andres R. Glucose Clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-E223, 1979.
22. Eriksson JW, Smith U, Waagstein F, Wysocki M, Jansson PA. Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? Diabetes 48: 1572-1578, 1999.
23. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Diabetol Int 1: 2-20, 2010.
24. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40: 872-879, 2002.
25. Muscogiuri G, Chavez AO, Gastaldelli A, et al. The crosstalk between insulin and rennin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol 6: 301-312, 2008.
26. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/ angiotensin II crosstalk. J Clin Invest 100: 2158-2169, 1997.
27. Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43: 1003-1010, 2004.
28. de Vinuesa SG, Goicoechea M, Kanter J, et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 17: S206-S212, 2006.
29. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist wth selective PPAR-modulating activity. Hypertension 43: 993-1002, 2004.
30. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099, 2001.
31. Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 31: 7-13, 2008.
32. Fliser D, Buchholz K, Haller H for the E Uropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive ptients with microinflammation. Circulation 110: 1103-1107, 2004.
33. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.